Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Bullboard Posts
Post by TexasTea20on Jan 16, 2017 3:29pm
178 Views
Post# 25714148

CT thoughts

CT thoughts
The "trial" as described in the release appears to be more of a Pharnacokinetic / Pharmacodydnamic initiative. Its not looking at efficacy but rather rate of absorption, bioavailability and distribution. This should not require many "patients", take particularly long or be that expensive. How fast, how much and where does the active ingredient preferably end up. For example, a THC only strip vs a CBD only strip vs a THC/CBD combo strip would be distributed differently (target tissue) in the body.

This "trail" is as much about seperating the nanoparticle technology and LDS from the pack. The look alikes, the incorrectly described and the less reproducable formats. The pretenders.

My thought is that in addition to validating the superiority of the nanoparticle delivery method what this also sets up is CannaStrips actually being viewed as a drug (yes I know) in the sense that you can know exactly how much active ingredient is being delivered and to what tissues. I suspect that this initiative alone will bring interested third-parites (pehaps pharmas) out of the woods. It can now be credibly studied, assayed and trialed down the road. Very cool.

Key thing though is any user, recreational or medical, can know with certainty what they are getting in terms of active ingredient. Even if you know the amout of active incredient in the dose you can't do that reproducably unless the delivery system allows a more direct absorption into the bloodstream avoiding poor absorption and by passing the liver.

Dr. Sanderson and the nanoparticle delivery method are the reasons why I own some of the stock. They are on the right track.  IMHO

Bullboard Posts